


Amendments to the Claims

1. (Previously Presented) A compound of formula I:



(I)

wherein:

Ar^1 is a cyclic group optionally substituted with one to five groups selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ alkylaryl, phenyl, aryl, -O-aryl, heteroaryl, cycloalkyl, C₁-C₈ alkylcycloalkyl, cyano, $-(\text{CH}_2)_n\text{NR}^6\text{R}^6$, C₁-C₈ haloalkyl, C₁-C₈ haloalkoxy, halo, $(\text{CH}_2)_n\text{COR}^6$, $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$, $-(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, heterocyclic, and C₁-C₈ alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, C₁-C₈ alkoxyalkyl, C₁-C₈ haloalkoxy, C₁-C₈ alkyl, halo, C₁-C₈ haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;

L^1 is a bond, -CH₂-, -CH₂CH₂-, -SCH₂-, -OCH₂-, -CH₂SCH₂-, -CH₂OCH₂-, -OCH₂CH₂SCH₂-, or a divalent linker represented by the formula $\text{X}_2-(\text{CR}^3\text{R}^4)_m-\text{X}_3$ where X_2 is attached to Ar^1 and X_3 is attached to Ar^2 wherein R^3 and R^4 are independently selected from a bond, hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenylene, C₂-C₈ alkynyl, phenyl, aryl, C₁-C₈ alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substituents independently selected from oxo, nitro, cyano, C₁-C₈ alkyl, aryl, halo, hydroxy, C₁-C₈ alkoxy, C₁-C₈ haloalkyl, $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^6$, and $(\text{CH}_2)_n\text{CONR}^6\text{R}^6$;

X_2 is independently oxygen, -CH, -CONH(CR³R⁴)_m, -NHCO(CR³R⁴)_m, - (CR³R⁴)_m, -CHR⁶, -NR⁵, S, SO, SO₂, -O(CR³R⁴)_m, or -S(CR³R⁴)_m;

X_3 is independently oxygen, -C, -CH, -CHR⁶, - (CR³R⁴)_m, -NR⁵, S, SO, or SO₂;

Ar^2 is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar^2 is optionally substituted with one to three substituents independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, hydroxy, C₁-C₈ alkoxy, C₁-C₈ alkylaryl, phenyl, aryl, C₃-C₈ cycloalkyl, C₁-C₈ alkylcycloalkyl, cyano, C₁-C₈ haloalkyl, halo,

$(\text{CH}_2)_n\text{C}(\text{O})\text{R}^6$, $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^6$, $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$, $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, and $\text{C}_1\text{-C}_8$ alkylheterocyclic;

Ar^3 is an optionally substituted bicyclic aromatic or non-aromatic group;

L^2 is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or a divalent linker represented by the formula $\text{X}_4-(\text{CR}^3\text{R}^4)_m-\text{X}_5$; wherein X_4 is selected from the group consisting of C, $-\text{CH}$, CHR^6 , $-\text{CO}$, O, $-\text{NR}^5$, $-\text{NC}(\text{O})-$, $-\text{NC}(\text{S})-$, $-\text{C}(\text{O})\text{NR}^5$, $-\text{NR}^6\text{C}(\text{O})\text{NR}^6$, $-\text{NR}^6\text{C}(\text{S})\text{NR}^6$, $-\text{SO}_2\text{NR}^7$, $-\text{NRSO}_2\text{R}^7$, and $-\text{NR}^6\text{C}(\text{NR}^5)\text{NR}^6$;

X_5 is selected from the group consisting of O, $-\text{CH}_2$, $-\text{CH}$, $-\text{O}(\text{CR}^3\text{R}^4)_m$, $\text{NR}^3(\text{CR}^3\text{R}^4)_m$, SO_2 , S, and SCH_3 ; wherein the group $\text{X}_4-(\text{CR}^3\text{R}^4)_m-\text{X}_5$ imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or divalent linker;

R^1 and R^2 are independently hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylaryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, $(\text{CH}_2)_n\text{C}(\text{O})\text{OR}^5$, $(\text{CH}_2)_n\text{C}(\text{O})\text{R}^5$, $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$, and $(\text{CH}_2)_n\text{NSO}_2\text{R}^5$; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups independently selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, phenyl, and alkylaryl; and wherein R^1 and R^2 may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylaryl, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, oxo, halo amino, and $(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^6\text{R}^6$;

R^5 is hydrogen, CN, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_5\text{-C}_8$ alkylaryl, $(\text{CH}_2)_n\text{NSO}_2\text{C}_1\text{-C}_8$ alkyl, $(\text{CH}_2)_n\text{NSO}_2\text{phenyl}$, $(\text{CH}_2)_n\text{NSO}_2\text{aryl}$, $-\text{C}(\text{O})\text{C}_1\text{-C}_8$ alkyl, or $-\text{C}(\text{O})\text{OC}_1\text{-C}_8$ alkyl; and

R^6 and R^6 are each independently hydrogen, $\text{C}_1\text{-C}_8$ alkyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, or $\text{C}_3\text{-C}_8$ cycloalkyl;

R^7 is hydrogen, $\text{C}_1\text{-C}_8$ alkyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl, or $\text{C}_3\text{-C}_8$ cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8;

or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

2. (Original) A compound according to Claim 1 wherein the group Ar^1 is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. (Original) A compound according to Claim 1 wherein the group L^1 is a linker selected from the group consisting of: $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{SCH}_2-$, $-\text{CH}_2\text{OCH}_2-$, or $-\text{OCH}_2\text{CH}_2\text{SCH}_2-$.

4. (Original) A compound according to Claim 1 wherein Ar^3 is an aromatic group selected from the group consisting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.

5. (Original) A compound of Claim 1 wherein Ar^2 is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.

6. (Original) A compound according to Claim 1 wherein the linker (L^2) is: $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

7. (Original) A compound according to Claim 1 wherein R^1 and R^2 combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidiny.

8. (Original) A compound according to Claim 1 wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.

9. (Cancelled)

10. (Cancelled)


11. (Cancelled)

12. (Original) A compound according to Claim 1 wherein at least one of L^1 and L^2 has a chain length of 3 to 5 atoms.

13. (Previously Presented) A compound selected from the group consisting of: Dimethyl- $\{6-[5-(2\text{-phenoxy-ethylsulfanylmethyl})-[1,3,4]\text{oxadiazol-2-yl}]-\text{benzofuran-2-ylmethyl}\}$ -amine oxalate,
Dimethyl- $\{5-[5-(2\text{-phenoxy-ethylsulfanylmethyl})-[1,3,4]\text{oxadiazol-2-yl}]-\text{benzofuran-2-ylmethyl}\}$ -amine oxalate,

ylmethyl}-amine oxalate,
{1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,
Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,
{1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,
Dimethyl-{1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,
Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine malate,
Dimethyl-{1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,
Dimethyl-{4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,
Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,
2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole malate,
1-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-piperidine,
2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethylthio)methyl]-1,3,4-oxadiazol-5-yl}isindolin-1-one,
and pharmaceutically acceptable salt, solvate, enantiomer, prodrug, diastereomer or mixture thereof.

14. (Original) A compound selected from the group consisting of:



or pharmaceutically acceptable salt, racemate, solvate, enantiomer or diastereomer or mixture of diastereomers thereof.

15. (Cancelled)

16. (Cancelled)

17. (Previously Presented) A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of Claim 1.

18. (Cancelled)

19. (Previously Presented) A pharmaceutical formulation comprising a compound of Claim 1 and a pharmaceutical carrier.

20. (Cancelled)